Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 6.24% is 174% above its 1-year average of -8.39%, near the high end of its 1-year range (-24.78%–6.24%).
As of the fiscal period ended Tuesday, June 30, 2026. 321.51% above its 12-month average of -2.82%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 6.24%.
RETURN ON EQUITY (ROE)
6.24%
RETURN ON EQUITY (ROE) AVG TTM
-2.82%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+321.51%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.55%
median of 499 covered companies
CURRENT VS SECTOR MEDIAN
+116.19%
vs the sector median at left
BillionToOne, Inc.
Market Cap
$4.84B
Return on Equity (ROE)
6.24%
TTM Avg
-2.82%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.93B
Return on Equity (ROE)
-79.37%
TTM Avg
-38.23%
3Y Avg
-43.73%
5Y Avg
-49.41%
Market Cap
$4.81B
Return on Equity (ROE)
N/A
TTM Avg
-23.20%
3Y Avg
-51.91%
5Y Avg
-56.25%
Market Cap
$5.04B
Return on Equity (ROE)
-161.00%
TTM Avg
-110.38%
3Y Avg
-86.51%
5Y Avg
-75.97%
Market Cap
$4.72B
Return on Equity (ROE)
-2.55%
TTM Avg
-28.50%
3Y Avg
-30.36%
5Y Avg
-30.19%
Market Cap
$4.68B
Return on Equity (ROE)
3.43%
TTM Avg
-1.67%
3Y Avg
-7.64%
5Y Avg
-9.04%
Market Cap
$5.10B
Return on Equity (ROE)
8.67%
TTM Avg
8.42%
3Y Avg
7.80%
5Y Avg
5.80%
Market Cap
$4.67B
Return on Equity (ROE)
-38.51%
TTM Avg
-50.16%
3Y Avg
-65.11%
5Y Avg
-61.13%
Market Cap
$5.16B
Return on Equity (ROE)
-70.85%
TTM Avg
-75.76%
3Y Avg
-70.25%
5Y Avg
-57.77%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BillionToOne, Inc. (BLLN) | $4.84B | 6.24% | -2.82% | N/A | N/A |
| Erasca, Inc. (ERAS)vs › | $4.93B | -79.37% | -38.23% | -43.73% | -49.41% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.81B | N/A | -23.20% | -51.91% | -56.25% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.04B | -161.00% | -110.38% | -86.51% | -75.97% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.72B | -2.55% | -28.50% | -30.36% | -30.19% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 3.43% | -1.67% | -7.64% | -9.04% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 8.67% | 8.42% | 7.80% | 5.80% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.67B | -38.51% | -50.16% | -65.11% | -61.13% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.16B | -70.85% | -75.76% | -70.25% | -57.77% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.56B | -44.68% | -52.94% | -55.51% | -46.01% |
ROE
6.2%
ROA
4.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 6.24% |
| 2026-03-31 | 4.99% |
| 2025-12-31 | 0.68% |
| 2025-09-30 | -7.90% |
| 2025-06-30 | -18.10% |
| 2025-03-31 | -19.89% |
| 2024-12-31 | -24.78% |
